Bill Cimino, CEO, explains how The GID Group’s SVF-2 device and therapy isolates the right cells to effectively heal damaged tissue caused by osteoarthritis of the knee.

Dale Tomrdle, VP Finance & Operations, explains how The GID Group’s SVF-2 device and therapy provides a potential alternative treatment option to total knee replacement.

Dale Tomrdle, VP Finance & Operations, explains how The GID Group’s SVF-2 device and therapy helps relieve a $200 billion annual U.S. osteoarthritis healthcare burden.

Victoria Good, Director of Clinical Affairs, explains how The GID Group’s FDA-approved clinical trial measuring safety and efficacy showed 70 percent of participating patients responding more than placebo and reporting a median 85 percent improvement in pain and function.